GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmesis International Ltd (SGX:BFK) » Definitions » EV-to-EBITDA

Pharmesis International (SGX:BFK) EV-to-EBITDA : -8.90 (As of May. 29, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Pharmesis International EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Pharmesis International's enterprise value is S$3.55 Mil. Pharmesis International's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was S$-0.40 Mil. Therefore, Pharmesis International's EV-to-EBITDA for today is -8.90.

The historical rank and industry rank for Pharmesis International's EV-to-EBITDA or its related term are showing as below:

SGX:BFK' s EV-to-EBITDA Range Over the Past 10 Years
Min: -77.02   Med: -0.65   Max: 17.26
Current: -8.9

During the past 13 years, the highest EV-to-EBITDA of Pharmesis International was 17.26. The lowest was -77.02. And the median was -0.65.

SGX:BFK's EV-to-EBITDA is ranked worse than
100% of 715 companies
in the Drug Manufacturers industry
Industry Median: 14.5 vs SGX:BFK: -8.90

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-29), Pharmesis International's stock price is S$0.08. Pharmesis International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was S$-0.035. Therefore, Pharmesis International's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Pharmesis International EV-to-EBITDA Historical Data

The historical data trend for Pharmesis International's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmesis International EV-to-EBITDA Chart

Pharmesis International Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.77 -11.22 4.39 -57.77 -11.52

Pharmesis International Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.39 - -57.77 - -11.52

Competitive Comparison of Pharmesis International's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Pharmesis International's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmesis International's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pharmesis International's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Pharmesis International's EV-to-EBITDA falls into.



Pharmesis International EV-to-EBITDA Calculation

Pharmesis International's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=3.550/-0.399
=-8.90

Pharmesis International's current Enterprise Value is S$3.55 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pharmesis International's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was S$-0.40 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmesis International  (SGX:BFK) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Pharmesis International's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.08/-0.035
=At Loss

Pharmesis International's share price for today is S$0.08.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pharmesis International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was S$-0.035.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Pharmesis International EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Pharmesis International's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmesis International (SGX:BFK) Business Description

Traded in Other Exchanges
N/A
Address
5 Kallang Sector, No. 03-02, Singapore, SGP, 349279
Pharmesis International Ltd is an investment holding company. The company manufactures pharmaceutical products in the form of tablets, granules, pills, and other forms. Its geographical segments are Western drugs, which are chemically formulated drugs and are marketed under the Kinna brand; TCM formulated drugs, which refer to Traditional Chinese Medicine and are marketed under the Longlife brand; and Distribution. The company derives revenue from the sale of medicines to domestic customers in China.

Pharmesis International (SGX:BFK) Headlines